Analyst Ratings For Charles River Laboratories Intl. Inc (NYSE:CRL)
Today, Credit Suisse Group lowered its price target on Charles River Laboratories Intl. Inc (NYSE:CRL) to $121.00 per share.
There are 8 Buy Ratings, 5 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Charles River Laboratories Intl. Inc (NYSE:CRL) is Buy with a consensus target price of $123.3846 per share, a potential 2.72% upside.
Some recent analyst ratings include
- 7/17/2018-Charles River Laboratories Intl. Inc (NYSE:CRL) gets upgraded to Outperform by Royal Bank of Canada with a price target of $131.00
- 6/15/2018-Charles River Laboratories Intl. Inc (NYSE:CRL) gets upgraded to Overweight by KeyCorp with a price target of $130.00
Recent Insider Trading Activity For Charles River Laboratories Intl. Inc (NYSE:CRL)
Charles River Laboratories Intl. Inc (NYSE:CRL) has insider ownership of 2.10% and institutional ownership of 97.76%.
- On 8/13/2018 David Ross Smith, Insider, sold 1,249 with an average share price of $120.05 per share and the total transaction amounting to $149,942.45.
- On 7/23/2018 Davide Molho, COO, sold 11,600 with an average share price of $125.00 per share and the total transaction amounting to $1,450,000.00.
- On 7/17/2018 Birgit Girshick, Insider, sold 3,978 with an average share price of $119.90 per share and the total transaction amounting to $476,962.20.
- On 7/17/2018 Davide Molho, COO, sold 11,126 with an average share price of $120.00 per share and the total transaction amounting to $1,335,120.00.
- On 7/2/2018 James C Foster, CEO, sold 5,005 with an average share price of $110.80 per share and the total transaction amounting to $554,554.00.
- On 6/25/2018 George Massaro, Director, sold 300 with an average share price of $115.55 per share and the total transaction amounting to $34,665.00.
- On 5/14/2018 George Massaro, Director, sold 1,218 with an average share price of $107.19 per share and the total transaction amounting to $130,557.42.
About Charles River Laboratories Intl. Inc (NYSE:CRL)
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Recent Trading Activity for Charles River Laboratories Intl. Inc (NYSE:CRL)
Shares of Charles River Laboratories Intl. Inc closed the previous trading session at 120,21 +0,65 0,54 % with shares trading hands.